Information

1.2: Cells- The Bio of Biochemistry - Biology

1.2: Cells- The Bio of Biochemistry - Biology


We are searching data for your request:

Forums and discussions:
Manuals and reference books:
Data from registers:
Wait the end of the search in all databases.
Upon completion, a link will appear to access the found materials.

1.2: Cells- The Bio of Biochemistry

Doctor of Philosophy (PhD) Degree in the field of Biochemistry and Cell Biology

Upon completing the PhD degree in the field of Biochemistry and Cell Biology, students will be able to:

  1. Develop a comprehensive knowledge of current and past research accomplishments and techniques in biochemistry and cell biology.
  2. Demonstrate independent problem solving and critical thinking skills.
  3. Demonstrate effective written, oral, and visual communication skills required to articulate scientific findings and significance via publications, seminars, and a thesis describing independent research.

Cell Biology

Cell biology aims to understand the structure and physiological function of individual cells, how they interact with their environment, and how large numbers of cells coordinate with each other to form tissues and organisms. As such, cell biology is at the heart of all biological sciences and key to understanding the development and progression of human diseases.

Projects in our department are directed toward exploring and defining key physiological, cellular and molecular pathways that drive cell proliferation and differentiation, signaling, migration, metabolism and autophagy, and more – and a major focus of our studies is on understanding the underlying cause of wide-spread human disease including diabetes, cancer, inflammation and fibrosis. We use different model systems for our studies, ranging from cell lines and organotypic cultures to various animal models and combine diverse experimental approaches including a wide variety of cell-based assays, microscopy, molecular biology, genetics and genomics, biochemistry, genome engineering and in vivo studies. More information on the individual projects can be found under the links below.

Faculty conducting research in these areas:

Mitosis, transcription, chromatin structure

G protein signaling circuits in the molecular basis of disease

Mechanisms of tissue fibrosis, aortic aneurysm, and mechanotransduction

RNA metabolism during stress

Genomic Regulation of Metabolism, Nuclear-Mitochondria Communication

Assistant Professor
Investigator, NEIDL

Role of viral proteases in shaping virus-host interactions

purinoreceptors, EGFR receptors, confocal imaging, wound repair, cell communication and migration

Stem Cells, Cancer biology, Organ development, Hippo pathway signaling

Biochemistry


References

The Diabetes Control and Complications Trial Research Group. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. N. Engl. J. Med. 329, 977–986 (1993).

UK Prospective Diabetes Study (UKPDS) Group. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet 352, 837–853 (1998).

Wei, M., Gaskill, S. P., Haffner, S. M. & Stern, M. P. Effects of diabetes and level of glycemia on all-cause and cardiovascular mortality. The San Antonio Heart Study. Diabetes Care 7, 1167–1172 (1998).

Ebara, T. et al. Delayed catabolism of apoB-48 lipoproteins due to decreased heparan sulfate proteoglycan production in diabetic mice. J. Clin. Invest. 105, 1807–1818 (2000).

Ginsberg, H. N. Insulin resistance and cardiovascular disease. J. Clin. Invest. 106, 453–458 (2000).

Lusis, A. J. Atherosclerosis. Nature 407, 233–241 (2000).

Hsueh, W. A. & Law, R. E. Cardiovascular risk continuum: implications of insulin resistance and diabetes. Am. J. Med. 105, 4S–14S (1998).

Jiang, Z. Y. et al. Characterization of selective resistance to insulin signaling in the vasculature of obese Zucker (fa/fa) rats. J. Clin. Invest. 104, 447–457 (1999).

Williams, S. B. et al. Acute hyperglycemia attenuates endothelium-dependent vasodilation in humans in vivo. Circulation 97, 1695–1701 (1998).

Du, X. L. et al. Hyperglycemia-induced mitochondrial superoxide overproduction activates the hexosamine pathway and induces plasminogen activator inhibitor-1 expression by increasing Sp1 glycosylation. Proc. Natl Acad. Sci. USA 97, 12222–12226 (2000).

Temelkova-Kurktschiev, T. S. et al. Postchallenge plasma glucose and glycemic spikes are more strongly associated with atherosclerosis than fasting glucose or HbA1c levels. Diabetes Care 12, 1830–1834 (2000).

Wilson, D. K., Bohren, K. M., Gabbay, K. H. & Quiocho, F. A. An unlikely sugar substrate site in the 1.65 A structure of the human aldose reductase holoenzyme implicated in diabetic complications. Science 257, 81–84 (1992).

Xia, P., Kramer, R. M. & King, G. L. Identification of the mechanism for the inhibition of Na,K-adenosine triphosphatase bv hyperglycemia involving activation of protein kinase C and cytosolic phospholipase A2. J. Clin. Invest. 96, 733–740 (1995).

Williamson, J. R. et al. Hyperglycemic pseudohypoxia and diabetic complications. Diabetes 42, 801–813 (1993).

Garcia Soriano, F. et al. Diabetic endothelial dysfunction: the role of poly(ADP-ribose) polymerase activation. Nature Med. 7, 108–113 (2001).

Lee, A. Y. & Chung, S. S. Contributions of polyol pathway to oxidative stress in diabetic cataract. FASEB J. 13, 23–30 (1999).

Engerman, R. L., Kern, T. S. & Larson, M. E. Nerve conduction and aldose reductase inhibition during 5 years of diabetes or galactosaemia in dogs. Diabetologia 37, 141–144 (1994).

Sorbinil Retinopathy Trial Research Group. A randomized trial of sorbinil, an aldose reductase inhibitor, in diabetic retinopathy. Arch. Ophthalmol. 108, 1234–1244 (1990).

Greene, D. A., Arezzo, J. C. & Brown, M. B. Effect of aldose reductase inhibition on nerve conduction and morphometry in diabetic neuropathy. Zenarestat Study Group. Neurology 53, 580–591 (1999).

Stitt, A. W. et al. Advanced glycation end products (AGEs) co-localize with AGE receptors in the retinal vasculature of diabetic and of AGE-infused rats. Am. J. Pathol. 150, 523–528 (1997).

Horie, K. et al. Immunohistochemical colocalization of glycoxidation products and lipid peroxidation products in diabetic renal glomerular lesions. Implication for glycoxidative stress in the pathogenesis of diabetic nephropathy. J. Clin. Invest. 100, 2995–2999 (1997).

Degenhardt, T. P., Thorpe, S. R. & Baynes, J. W. Chemical modification of proteins by methylglyoxal. Cell Mol. Biol. 44, 1139–1145 (1998).

Wells-Knecht, K. J. et al. Mechanism of autoxidative glycosylation: identification of glyoxal and arabinose as intermediates in the autoxidative modification of proteins by glucose. Biochemistry 34, 3702–3709 (1995).

Thornalley, P. J. The glyoxalase system: new developments towards functional characterization of a metabolic pathway fundamental to biological life. Biochem J. 269, 1–11 (1990).

Suzuki, K. et al. Overexpression of aldehyde reductase protects PC12 cells from the cytotoxicity of methylglyoxal or 3-deoxyglucosone. J. Biochem. 123, 353–357 (1998).

Soulis-Liparota T., Cooper, M., Papazoglou, D., Clarke, B. & Jerums, G. Retardation by aminoguanidine of development of albuminuria, mesangial expansion, and tissue fluorescence in streptozocin-induced diabetic rat. Diabetes 40, 1328–1334 (1991).

Nakamura, S. et al. Progression of nephropathy in spontaneous diabetic rats is prevented by OPB-9195, a novel inhibitor of advanced glycation. Diabetes 46, 895–899 (1997).

Hammes, H-P. et al. Aminoguanidine treatment inhibits the development of experimental diabetic retinopathy. Proc. Natl Acad. Sci. USA 88, 11555–11559 (1991).

Giardino, I., Edelstein, D. & Brownlee, M. Nonenzymatic glycosylation in vitro and in bovine endothelial cells alters basic fibroblast growth factor activity. A model for intracellular glycosylation in diabetes. J. Clin. Invest. 94, 110–117 (1994).

Shinohara, M. et al. Overexpression of glyoxalase-I in bovine endothelial cells inhibits intracellular advanced glycation endproduct formation and prevents hyperglycemia-induced increases in macromolecular endocytosis. J. Clin. Invest. 101, 1142–1147 (1998).

Maisonpierre, P. C. et al. Angiopoietin-2, a natural antagonist for Tie2 that disrupts in vivo angiogenesis. Science 277, 55–60 (1997).

Tanaka, S., Avigad, G., Brodsky, B. & Eikenberry, E. F. Glycation induces expansion of the molecular packing of collagen. J. Mol. Biol. 203, 495–505 (1988).

Huijberts, M. S. P. et al. Aminoguanidine treatment increases elasticity and decreases fluid filtration of large arteries from diabetic rats. J. Clin. Invest. 92, 1407–1411 (1993).

Tsilbary, E. C. et al. The effect of nonenzymatic glucosylation the binding of the main noncollagenous NC1 domain to type IV collagen. J. Biol. Chem. 263, 4302–4308 (1990).

Charonis, A. S. et al. Laminin alterations after in vitro nonenzymatic glucosylation. Diabetes 39, 807–814 (1988).

Haitoglou, C. S., Tsilibary, E. C., Brownlee, M. & Charonis, A. S. Altered cellular interactions between endothelial cells and nonenzymatically glucosylated laminin/type IV collagen. J. Biol. Chem. 267, 12404–12407 (1992).

Federoff, H. J., Lawrence, D. & Brownlee, M. Nonenzymatic glycosylation of laminin and the laminin peptide CIKVAVS inhibits neurite outgrowth. Diabetes 42, 509–513 (1993).

Li, Y. M. et al. Molecular identity and cellular distribution of advanced glycation endproduct receptors: relationship of p60 to OST-48 and p90 to 80K-H membrane proteins. Proc. Natl Acad. Sci. USA 93, 11047–11052 (1996).

Smedsrod, B. et al. Advanced glycation end products are eliminated by scavenger-receptor-mediated endocytosis in hepatic sinusoidal kupffer and endothelial cells. Biochem J. 322, 567–573 (1997).

Vlassara, H. et al. Identification of galectin-3 as a high-affinity binding protein for advanced glycation end products (AGE): a new member of the AGE-receptor complex. Mol. Med. 1, 634–646 (1995).

Neeper, M. et al. Cloning and expression of RAGE: a cell surface receptor for advanced glycosylation end products of proteins. J. Biol. Chem. 267, 14998–15004 (1992).

Vlassara, H. et al. Cachectin/TNF and IL-1 induced by glucose-modified proteins: role in normal tissue remodeling. Science 240, 1546–1548 (1988).

Kirstein, M., Aston, C., Hintz, R. & Vlassara, H. Receptor-specific induction of insulin-like growth factor I in human monocytes by advanced glycosylation end product-modified proteins. J. Clin. Invest. 90, 439–446 (1992).

Abordo, E. A., Westwood, M. E. & Thornalley, P. J. Synthesis and secretion of macrophage colony stimulating factor by mature human monocytes and human monocytic THP-1 cells induced by human serum albumin derivatives modified with methylglyoxal and glucose-derived advanced glycation endproducts. Immunol. Lett. 53, 7–13 (1996).

Skolnik, E. Y. et al. Human and rat mesangial cell receptors for glucose-modified proteins: potential role in kidney tissue remodelling and diabetic nephropathy. J. Exp. Med. 174, 931–939 (1991).

Doi, T. et al. Receptor specific increase in extracellular matrix productions in mouse mesangial cells by advanced glycosylation end products is mediated via platelet derived growth factor. Proc. Natl Acad. Sci. USA 89, 2873–2877 (1992).

Schmidt, A. M. et al. Advanced glycation endproducts interacting with their endothelial receptor induce expression of vascular cell adhesion molecule-1 (VCAM-1) in cultured human endothelial cells and in mice: a potential mechanism for the accelerated vasculopathy of diabetes. J. Clin. Invest. 96, 1395–1403 (1995).

Lu, M. et al. Advanced glycation end products increase retinal vascular endothelial growth factor expression. J. Clin. Invest. 101, 1219–1224 (1998).

Park, L. et al. Suppression of accelerated diabetic atherosclerosis by the soluble receptor for advanced glycation endproducts. Nature Med. 4, 1025–1031 (1998).

Yan, S. D. et al. Enhanced cellular oxidant stress by the interaction of advanced glycation end products with their receptors/binding proteins. J. Biol. Chem. 269, 9889–9897 (1994).

Lander, H. M. et al. Activation of the receptor for advanced glycation end products triggers a p21(ras)-dependent mitogen-activated protein kinase pathway regulated by oxidant stress. J. Biol. Chem. 272, 17810–17814 (1997).

Yamagishi, S. et al. Advanced glycation endproducts inhibit prostacyclin production and induce plasminogen activator inhibitor-1 in human microvascular endothelial cells. Diabetologia 41, 1435–1441 (1998).

Tsuji, H. et al. Ribozyme targeting of receptor for advanced glycation end products in mouse mesangial cells. Biochem. Biophys. Res. Commun. 245, 583–588 (1998).

Koya, D. & King, G. L. Protein kinase C activation and the development of diabetic complications. Diabetes 47, 859–866 (1998).

Xia, P. et al. Characterization of the mechanism for the chronic activation of diacylglycerol-protein kinase C pathway in diabetes and hypergalactosemia. Diabetes 43, 1122–1129 (1994).

Koya, D. et al. Characterization of protein kinase C beta isoform activation on the gene expression of transforming growth factor-beta, extracellular matrix components, and prostanoids in the glomeruli of diabetic rats. J. Clin. Invest. 100, 115–126 (1997).

Portilla, D. et al. Etomoxir -induced PPARalpha-modulated enzymes protect during acute renal failure. Am. J. Physiol. Renal Physiol. 278, F667–F675 (2000).

Keogh, R. J., Dunlop, M. E. & Larkins R. G. . Effect of inhibition of aldose reductase on glucose flux, diacylglycerol formation, protein kinase C, and phospholipase A2 activation. Metabolism 46, 41–47 (1997).

Ishii, H. et al. Amelioration of vascular dysfunctions in diabetic rats by an oral PKC beta inhibitor. Science 272, 728–731 (1996).

Craven, P. A., Studer, R. K. & DeRubertis, F. R. Impaired nitric oxide-dependent cyclic guanosine monophosphate generation in glomeruli from diabetic rats. Evidence for protein kinase C-mediated suppression of the cholinergic response. J. Clin. Invest. 93, 311–320 (1994).

Ganz, M. B. & Seftel, A. Glucose-induced changes in protein kinase C and nitric oxide are prevented by vitamin E. Am. J. Physiol. 278, E146–E152 (2000).

Kuboki, K. et al. Regulation of endothelial constitutive nitric oxide synthase gene expression in endothelial cells and in vivo a specific vascular action of insulin. Circulation 101, 676–681 (2000).

Glogowski, E. A., Tsiani, E., Zhou, X., Fantus, I. G. & Whiteside, C. High glucose alters the response of mesangial cell protein kinase C isoforms to endothelin-1. Kidney Int. 55, 486–499 (1999).

Hempel, A. et al. High glucose concentrations increase endothelial cell permeability via activation of protein kinase C alpha. Circ. Res. 81, 363–371 (1997).

Williams, B., Gallacher, B., Patel, H. & Orme, C. Glucose-induced protein kinase C activation regulates vascular permeability factor mRNA expression and peptide production by human vascular smooth muscle cells in vitro. Diabetes 46, 1497–1503 (1997).

Studer, R. K., Craven, P. A. & DeRubertis, F. R. Role for protein kinase C in the mediation of increased fibronectin accumulation by mesangial cells grown in high-glucose medium. Diabetes 42, 118–126 (1993).

Koya, D. et al. Characterization of protein kinase C beta isoform activation on the gene expression of transforming growth factor-beta, extracellular matrix components, and prostanoids in the glomeruli of diabetic rats. J. Clin. Invest. 100, 115–126 (1997).

Craven, P. A., Studer, R. K., Felder, J., Phillips, S. & DeRubertis, F. R. Nitric oxide inhibition of transforming growth factor-beta and collagen synthesis in mesangial cells. Diabetes 46, 671–681 (1997).

Phillips, S. L., DeRubertis, F. R. & Craven, P. A. Regulation of the laminin C1 promoter in cultured mesangial cells. Diabetes 48, 2083–2089 (1999).

Feener, E. P. et al. Role of protein kinase C in glucose- and angiotensin II-induced plasminogen activator inhibitor expression. Contrib. Nephrol. 118, 180–187 (1996).

Pieper, G. M. & Riaz-ul-Haq, J. Activation of nuclear factor-kappaB in cultured endothelial cells by increased glucose concentration: prevention by calphostin C. Cardiovasc. Pharmacol. 30, 528–532 (1997).

Yerneni, K. K., Bai, W., Khan, B. V., Medford, R. M. & Natarajan, R. Hyperglycemia-induced activation of nuclear transcription factor kappaB in vascular smooth muscle cells. Diabetes 48, 855–864 (1999).

Koya, D. et al. Amelioration of accelerated diabetic mesangial expansion by treatment with a PKC beta inhibitor in diabetic db/db mice, a rodent model for type 2 diabetes. FASEB J. 14, 439–447 (2000).

Kolm-Litty, V., Sauer, U., Nerlich, A., Lehmann, R. & Schleicher, E. D. High glucose-induced transforming growth factor beta1 production is mediated by the hexosamine pathway in porcine glomerular mesangial cells. J. Clin. Invest. 101, 160–169 (1998).

Marshall, S., Bacote, V. & Traxinger, R. R. Discovery of a metabolic pathway mediating glucose-induced desensitization of the glucose transport system. Role of hexosamine biosynthesis in the induction of insulin resistance. J. Biol. Chem. 266, 4706–4712 (1991).

Hawkins, M. et al. Role of the glucosamine pathway in fat-induced insulin resistance. J. Clin. Invest. 99, 2173–2182 (1997).

Chen, Y. Q. et al. Sp1 sites mediate activation of the plasminogen activator inhibitor-1 promoter by glucose in vascular smooth muscle cells. J. Biol. Chem. 273, 8225–8231 (1998).

Goldberg, H. J., Scholey, J. & Fantus, I. G. Glucosamine activates the plasminogen activator inhibitor 1 gene promoter through Sp1 DNA binding sites in glomerular mesangial cells. Diabetes 49, 863–871 (2000).

Kadonaga, J. T., Courey, A. J., Ladika, J. & Tjian, R. Distinct regions of Sp1 modulate DNA binding and transcriptional activation. Science 242, 1566–1570 (1988).

Haltiwanger, R. S., Grove, K. & Philipsberg, G. A. Modulation of O-linked N-acetylglucosamine levels on nuclear and cytoplasmic proteins in vivo using the peptide O-GlcNAc-beta-N-acetylglucosaminidase inhibitor O-(2-acetamido-2-deoxy-D-glucopyranosylidene)amino-N-phenylcarbamate. J. Biol. Chem. 273, 3611–3617 (1998).

Hart, G. W. Dynamic O-linked glycosylation of nuclear and cytoskeletal proteins Annu. Rev. Biochem. 66, 315–335 (1997).

Du, X. D. et al. Hyperglycemia inhibits endothelial nitric oxide synthase activity by posttranslational modification at the AKT site. J. Clin. Invest. (in the press).

Lee, A. Y., Chung, S. K. & Chung, S. S. Demonstration that polyol accumulation is responsible for diabetic cataract by the use of transgenic mice expressing the aldose reductase gene in the lens. Proc. Natl Acad. Sci. USA 92, 2780–2784 (1995).

Nishikawa, T. et al. Normalizing mitochondrial superoxide production blocks three pathways of hyperglycaemic damage. Nature 404, 787–790 (2000).

Giugliano, D., Ceriello, A. & Paolisso, G. Oxidative stress and diabetic vascular complications. Diabetes Care 19, 257–267 (1996).

Giardino, I., Edelstein, D. & Brownlee, M. BCL-2 expression or antioxidants prevent hyperglycemia-induced formation of intracellular advanced glycation endproducts in bovine endothelial cells. J. Clin. Invest. 97, 1422–1428 (1996).

Korshunov, S. S., Skulachev, V. P. & Starkov, A. A. High protonic potential actuates a mechanism of production of reactive oxygen species in mitochondria. FEBS Lett. 416, 15–18 (1997).

Craven, R. P., Phillip, S. L., Melhem, M. F., Liachenko, J. & De Rubertis, F. R. Overexpression of Mn 2+ superoxide dismutase suppresses increases in collagen accumulation induced by culture in measangial cells in high media glucose. Metabolism (in the press).

Yamagishi, S. I., Edelstein, D., Du, X. L. & Brownlee, M. Hyperglycemia potentiates collagen-induced platelet activation through mitochondrial superoxide overproduction. Diabetes 50, 1491–1494 (2001).

Craven, P. A., Melham, M. F., Phillip, S. L. & DeRubertis, F. R. Overexpression of Cu 2+ /Zn 2+ superoxide dismutase protects against early diabetic glomerular injury in transgenic mice. Diabetes 50, 2114–2125 (2001).

Engerman, R. L. & Kern, T. S. Progression of incipient diabetic retinopathy during good glycemic control. Diabetes 36, 808–812 (1987).

The Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications Research Group. Retinopathy and nephropathy in patients with type 1 diabetes four years after a trial of intensive therapy. N. Engl. J. Med. 342, 381–389 (2000).

Quinn, M., Angelico, M. C., Warram, J. H. & Krolewski, A. S. Familial factors determine the development of diabetic nephropathy in patients with IDDM. Diabetologia 39, 940–945 (1996).

The Diabetes Control and Complications Trial Research Group. Clustering of long-term complications in families with diabetes in the diabetes control and complications trial. Diabetes 46, 1829–1839 (1997).

Wagenknecht, L. E. et al. Familial aggregation of coronary artery calcium in families with type 2 diabetes. Diabetes 50, 861–866 (2001).

Kowluru, R. A., Tang, J. & Kern, T. S. Abnormalities of retinal metabolism in diabetes and experimental galactosemia. VII. Effect of long-term administration of antioxidants on the development of retinopathy. Diabetes 50, 1938–1942 (2001).

Ting, H. H. et al. Vitamin C improves endothelium-dependent vasodilation in patients with non-insulin-dependent diabetes mellitus. J. Clin. Invest. 97, 22–28 (1996).

Heart Outcomes Prevention Evaluation Study Investigators. Effects of ramipril on cardiovascular and microvascular outcomes in people with diabetes mellitus: results of the HOPE study and MICRO-HOPE substudy. Lancet 355, 253–259 (2000).

Salvemini, D. et al. A nonpeptidyl mimic of superoxide dismutase with therapeutic activity in rats. Science 286, 304–306 (1999).

Coppey, L. J. et al. Brit. J. Pharmacol. 134, 21–29 (2001).


Cells become senescent in response to reaching the Hayflick limit on replication, or to potentially cancerous mutations, or a toxic environment and consequent cell damage, or signaling from other senescent cells. Senescence is nominally an irreversible state. Replication halts and the cell begins secreting pro-inflammatory signals to attract the attention of the immune system. Senescent cells are normally removed via programmed cell death or the actions of cytotoxic immune cells. With age the rate of creation increases and the rate of removal falls, however, leading to a growing number of senescent cells throughout the body. The signaling of that growing number of senescent cells in aged tissues causes chronic inflammation and disrupts tissue maintenance, leading to age-related disease.

What to do about this? Much of the focus of the research community is on senolytic approaches that force senescent cells into apoptosis and self-destruction, or that provoke the immune system into more efficient clearance of senescent cells. These therapies have achieved impressive results in mice, reversing age-related disease and many measures of aging. Some researchers are interested in the reversal of senescence, however: reprogramming cells in ways that overcome the regulatory processes that normally ensure continuation of the senescent state.

Is reversal of senescence a good idea? It seems likely that at least some senescent cells are senescent for a good reason. That they are damaged, and in some cases that damage is potentially cancerous. Reversing senescence may well produce short term gains that are similar to those of senolytic therapies, since in either case the harmful signaling produced by senescent cells is removed. But a significantly raised risk of cancer may be the cost of that approach.

Although partial reprogramming proved that senescent cells can be reverted, early termination of this reprogramming process is known to cause epigenetic dysregulation, resulting in dedifferentiated dysplastic cells such as renal cancer. Therefore, a novel therapeutic strategy without such critical limitations is highly needed. Cellular senescence is caused by complex interactions among biomolecules that govern cell cycle, DNA damage response, energy metabolism, and cytokine secretion. Recent studies showed that cellular senescence, previously considered as an irreversible biological phenomenon, can be reversed, but due to the nature of such complex interactions governing cellular senescence, the mechanism by which cellular senescence can be reversed has not been revealed.

Researchers reconstructed an ensemble of 5000 Boolean network models that can represent senescence, quiescence, and proliferation phenotypes by integrating information from the literature, network databases and phosphoprotein array data of dermal fibroblasts. In their models, cellular senescence is induced by simultaneous activation of DNA damage signal (doxorubicin) and growth signal (IGF-1 plus serum). They identified 3-phosphoinositide-dependent protein kinase 1 (PDK1) as the optimal protein target that can safely revert senescence to quiescence while avoiding uncontrolled proliferation, through extensive computer simulation analysis of the ensemble model. PDK1 forms a positive feedback structure along with AKT, IKBKB, and PTEN, that simultaneously control both nuclear factor κB, which controls cytokine secretion, and mTOR, which regulates cell growth.

In order to validate the simulation results, researchers conducted in vitro experiments and confirmed that when PDK1 was inhibited, various markers of cellular senescence are returned to normal and proliferation potential is restored. From wound healing assays and 3D reconstructed skin tissue experiments, they also reaffirmed that the reverted cells are able to respond appropriately to external stimuli. In particular, by observing dermal fibroblast within dermis along with keratinocyte within epidermis, 3D reconstructed skin tissue experiments verified that PDK1 inhibition promotes epidermal renewal and restores skin thickness, resulting in reversal of age-related skin degeneration.

Compounds from Natural Sources as Protein Kinase Inhibitors

Fisetin is shown in Figure 1 as an inhibitor of PDK1. A diet rich in plant polyphenols is probably a decent idea anyhow.

What does your senolytic research focus on?

There is a specific fatty acid made in small amounts in the body called dihomo-gamma-linoleic acid or DGLA. It's also present in tiny amounts in the diet. When I gave aged mice larger amounts of DGLA, they went from having quite a few senescent cells to having significantly fewer.

This presents a new therapeutic target. I identified a candidate compound using the DGLA metabolic pathway that works at a dose that is over 1,000 times lower than fisetin, so you can imagine we're quite excited by these results.

Like many biomedical discoveries, it was accidental. DGLA makes anti-inflammatory lipids, which help alleviate conditions such as rheumatoid arthritis. I was studying this aspect of DGLA when I was surprised to discover that it killed senescent cells.

My work is in its very early stages, and we've only studied a small number of mice, so it's too early for even tentative conclusions, although I'm obviously pleased that we've seen the elimination of a meaningful number of senescent cells in old mice. We'll be closely monitoring DGLA's positive effects as well as any negative effects on the mice.

How would DGLA be given to people?

We are several years away from that, because everything has to be perfect with mice before we even think about trials with people.

First, we have to figure out how DGLA is killing senescent cells in mice. Again, not all studies with mice yield similar results in humans, so we are very careful about how we convey our findings and possible future actions.

But being at the HNRCA, I have met USDA researchers and nutrition scientists, and discovered that some of those folks were developing DGLA-enriched soybeans. In one scenario, you might go out for sushi and get a little bowl of DGLA-enriched edamame as a side. By the time you're done eating, you've helped reduce the odds of getting some age-related pathology.

I don't know if it will play out that way, but it's an idea we're working toward. I also am working on therapies that elevate the amount of naturally occurring DGLA in senescent cells that I am very excited about, so this would be an alternative approach.

You are also studying ways to test senolytic therapies beyond such measures as improvement in distance walked, right?

Yes, I am developing a quick and easy test to tell if senolytic therapy is working. Testing for senolytic effectiveness is not really being done now-you just look for improvement in symptoms or functioning and essentially conclude that it's due to the therapy.

But we can't say that with full confidence. Currently, researchers obtain skin or fat samples from patients in these trials before and after senolytic treatment to look for senescent cells. But this is an invasive procedure and it's especially challenging for older people to undergo this testing.

One way to solve this dilemma is to identify a biomarker, a measurable compound that consistently and reliably can confirm an intervention's effectiveness. For example, we know that a certain lipid, dihomo-15d-PGJ2, accumulates in large amounts inside of senescent cells.

When we give a senolytic therapy that kills these cells in mice or human cells, this lipid is liberated. Detecting it in blood and urine is far less invasive, so that's what I'm working on now. Our aim is to be able to test people receiving senolytic therapy for the presence of dihomo-15d-PGJ2 in their blood and urine by the end of the summer.


Pre-Major Requirements

The Biological Sciences program at Sacramento State is one of the most highly sought after programs in Northern California. Due to the large number of applications, the program is now officially impacted. Students wishing to become Biological Science majors must complete a series of required lower division and then must apply for admission to the program. Check the department website for requirements, and it is highly recommended that interested students speak with an advisor at the Natural Sciences Advising Center (NSAC) as soon as possible.

Freshmen interested in the major are admitted as pre-Biological Science majors.

To change to the Biological Sciences major, pre-major students are required to complete the following courses and grade requirements and submit a Declaration of Major form to the Biological Science Department Office along with transcript copies.


Requirements for the Minor in Biochemistry and Cell Biology

Students pursuing the minor in Biochemistry and Cell Biology must complete:

The minor in Biochemistry and Cell Biology is intended for those with an interest in the life sciences but who may be majoring in other areas. This minor incorporates many of the life science core courses required for the health professions.

The courses listed below satisfy the requirements for this minor. In certain instances, courses not on this official list may be substituted upon approval of the minor’s academic advisor, or where applicable, the Program Director. (Course substitutions must be formally applied and entered into Degree Works by the minor's Official Certifier). Students and their academic advisors should identify and clearly document the courses to be taken.

Summary

Course List
Code Title Credit Hours
Total Credit Hours Required for the Minor in Biochemistry and Cell Biology Minimum of 44

Minor Requirements

Footnotes and Additional Information

Permissible Substitutions: MATH 105 or MATH 111 and MATH 112 may be substituted for MATH 101 MATH 106 may be substituted for MATH 102 CHEM 151 may be substituted for CHEM 121 or CHEM 111 CHEM 153 may be substituted for CHEM 123 or CHEM 113 CHEM 152 may be substituted for CHEM 122 or CHEM 112 , and CHEM 154 may be substituted for CHEM 124 or CHEM 114 CHEM 320 may be substituted for CHEM 212 PHYS 101 and PHYS 103 or PHYS 111 may be substituted for PHYS 125 PHYS 102 and PHYS 104 or PHYS 112 may be substituted for PHYS 126 .

Lecture courses are noted in Rice's Course Catalog with a course type of "lecture". These courses do not include courses listed with a course type of "lecture/laboratory".


Lecture 3: Biochemistry 2

Download the track from iTunes U or the Internet Archive.

Topics covered: Biochemistry 2

Instructors: Prof. Robert A. Weinberg

Lecture 10: Molecular Biolo.

Lecture 11: Molecular Biolo.

Lecture 12: Molecular Biolo.

Lecture 13: Gene Regulation

Lecture 14: Protein Localiz.

Lecture 15: Recombinant DNA 1

Lecture 16: Recombinant DNA 2

Lecture 17: Recombinant DNA 3

Lecture 18: Recombinant DNA 4

Lecture 19: Cell Cycle/Sign.

Lecture 26: Nervous System 1

Lecture 27: Nervous System 2

Lecture 28: Nervous System 3

Lecture 29: Stem Cells/Clon.

Lecture 30: Stem Cells/Clon.

Lecture 31: Molecular Medic.

Lecture 32: Molecular Evolu.

Lecture 33: Molecular Medic.

Lecture 34: Human Polymorph.

Lecture 35: Human Polymorph.

Good morning, class. Nice to see you again. Hope you had a great weekend. If you didn't, it wasn't because of the weather.

So here I am, once again a member of the walking wounded, and we're talking about carbohydrates today, as you may recall, or at least we were at the end of our discussion last time.

And, we made the point that these multiple hydroxyl groups on the carbohydrates, on the one hand, determine the identity of various kinds of sugars.

Just the orientation, the three-dimensional orientation of them, for one thing, and for another that these multiple hydroxyl groups represent the opportunity for forming covalent bonds with other monosaccharides as is indicated here in these disaccharides, or covalent bonds end-to-end to create large molecules, which will increasingly be the theme of our discussion today, i.e. when I talk about large molecules, we just used the phrase generically, macromolecules, since in principle these end to end joinings of molecules which involve the dehydration and the formation of these covalent bonds like right here can create molecules that are hundreds, indeed even thousands of subunits long.

So, here, if we're talking about a polymer, we refer to each one of these subunits of the polymer as being a monomer, and the aggregate as a whole as being a polymer.

Here, we touched upon the fact toward the end of last lecture, in fact, at the very end, that one can cross-link these long, linear chains of carbohydrates.

And here, we see the fact that glycogen, which is a form of glucose that is stored in our liver largely, and to a small extent in the muscles actually is cross-branched. So, if one draws on a much smaller scale a glycogen molecule, one might draw a picture that looks like this.

And it looks almost like a Christmas tree with multiple branches.

And, the purpose of this is actually to sequester the glucose, to store the glucose into metabolically inactive form until the time comes that the organism needs, once again, the energy that is stored in the glucose upon which occasion these bonds are rapidly broken down and the glucose is mobilized and put into the circulation for eventual disposition and use in certain, specific tissues.

While it's encumbered in these high molecular weight polymers, the glucose is essentially metabolically inactive.

The body doesn't realize it's there.

And, we can, as a consequence store large amounts of energy in these glycogen molecules.

And it can be stored there indefinitely.

Now, the fact is this idea of end-to-end polymerization that I just mentioned can be extended to other macromolecules which also become linked end-to-end in specific kinds of polymers.

And here, we are moving, now, into the notion of talking about amino acids.

And, we're talking about proteins.

If we look at an amino acid, what we see is it has an important structure like this.

Here's a central carbon ? for, in principle, the distinct side chains where R represents some side chain that can be any one of, as we'll see shortly, 20 distinct identities.

But, all the amino acids share in common the property that they have this overall structure.

And, as you may recall from our discussions of last week, at neutral pH, an amino acid of this sort, whatever R is, wouldn't look like this at all because the amine group would attract an extra proton, causing it to become positively charged.

And, the carboxyl group would release a proton, causing it to become negatively charged.

And, as you might deduce from this, at very low pHn due to the greatly increased concentration of protons, free protons in the solution, the equilibrium would be driven more in favor of reattaching a proton to the carboxyl group just because there are so many of these protons around.

Conversely, at very high pH, where the hydroxyl ions are in predominance, they obviously tend to scavenge protons, reducing the level of protons to very low levels in the water.

And, under very high pH conditions, this proton would be released and pulled away by the hydroxyl ions causing this amine group once again to return to its negative charge state.

Now, the fact of the matter is that these amino acids exist in a very specific three-dimensional configuration.

And that's illustrated much more nicely here than I could possibly draw on the board, which in any case would be hopeless.

And, you can see the principle that once you have four distinct side groups coming off of carbon, that there is, in principle, two different ways to create them.

And, this is sometimes called chirality.

Chiral, you see, is the form right here.

If I try, as much as I will, to superimpose one hand on top of another.

It doesn't work because they are mirror images of one another, which are asymmetrical.

And, as a consequence, we see a similar kind of relationship occurring here where we see that these two forms of amino acids could, in principle, exist.

And, they are not interchangeable unless one breaks one of the bonds and reforms it.

These two forms are called the L and the D, and it turns out that the L form is the one that's used by virtually all life forms on the planet, i.e. there was an arbitrary choice made sometime about 3 billion years ago or more to use one of the three dimensional configurations, and not to use the other.

The other is found in certain rare exceptions, but virtually all life forms on this planet use the L form.

That said, by the way, this indicates some of the arbitrary decisions that were made early during evolution because we could imagine on another planet if life were to exist there and it were to depend on amino acids, and that evolutionary system might have chosen the D form.

So, this is sort of a luck of the draw.

This is actually the way things evolved here.

And, what we begin to see, now, is if we talk about proteins or if we wanted to be more specific and use the more biochemical term ?polypeptide,? we see once again we have an end-to-end joining system which is a bit different from that which the monosaccharides employ to create long chains of glycogen or of starch because here we see once again a dehydration reaction where an amine group and a carboxyl group are caused to shed their hydroxyl and the proton, causing the formation of a peptide bond.

And here, we see this important, very important biochemical entity, a peptide bond consisting here of this carbonyl and this nitrogen fused in this specific way.

And, of course, if you recognize this as being a peptide bond, then you can understand why proteins are sometimes given the term ?polypeptide.?

In some cases, if one has very short stretches of amino acids linked end to end like this, we talk about these being oligopeptides, where ?oligo? is the general term used in biology to refer to a small number of things rather than a large number of things.

And, once again, we have, here, the possibility of extending this infinitely. There are no constraints, in principle, on making this 500, 1,000, even 2,000 amino acids long, where each one of these, once again, is an amino acid, and where once again I'm being very coy about the identities of R1 and R2, which, as I will indicate very shortly, can be one of 20 distinct alternatives.

Here, you see that we are continuing this process of peptide bond formation.

And most importantly here is the realization that there is a polarity of elongation here.

It doesn't move with equal probability left or right, or right to left.

We start at the amino end here.

This is the amino end, and this is the carboxyl end.

The amino end and the carboxyl end, and invariably, again because of the way life has evolved on this planet, the new amino acid is added on the carboxyl end.

And so, when one often talks about proteins, one refers to their N terminal, and to their C terminal ends, these referring obviously to the amino group at one end and a carboxyl and at the other end so that polarity is always a directed synthesis adding it on C-terminal end, in other words to use a short-hand notation, we think about proteins as going with this polarity N toward C.

Things are growing at the C terminal end progressively.

And, each time one can imagine the addition of an amino acid on the end of it.

So, again, it can be extended, in principle, indefinitely.

Keep in mind as well, something that's implicit in everything I'm telling you but I won't always mention it explicitly, and that is virtually every biochemical reaction is reversible.

And therefore, if one is able to form a peptide bond, one is able to break it down by biological means as well, i.e. by introducing a water molecule back in and thereby using the process of hydrolysis, which is the breakdown of a bond through the introduction of a water molecule to destroy the previously created bond.

To use an MIT phrase, the reversibility is intuitively obvious because if you are able to make a, well, I don't know if it?s still used, but it was used in the late Stone Age around here.

Anyhow, any biochemical action must be reversible because if, for example, this polymerization were irreversible, then all the protein that was ever synthesized on the surface of the planet over the last 3 1/2 billion years would accumulate progressively.

And obviously, that doesn't happen.

And therefore, macromolecular synthesis, to the extent that it proceeds forward, obviously must go the other direction as well.

And the resulting concentration of a complete protein is known as its steady state.

So we might make a protein at one rate and break it down at the same rate.

And its steady-state concentration represents the compromise between these two, i.e., the concentration of such a protein that we might observe at any one point in time.

Indeed, the term ?steady-state? could be expanded to any process in which there is a synthesis and there is a breakdown of something.

And the equilibrium concentration which results is, once again, called the steady-state of that molecule. Now, let's get down to the nitty-gritty, which is obviously something which we can't avoid for very long, which is to say the R's, i.e. the side chains.

Once again, here we see an arbitrary artifact of very early evolution in the biosphere because there are, in effect, 20 different side chains creating 20 distinct amino acids, which are used in proteins by all organisms on this planet.

Again, there are rare exceptions, certain fungi and certain bacteria are able to make unusual amino acids.

But these are the basic building blocks of virtually all life forms on the planet. 99.99% of all the protein that is created is synthesized through the polymerization of these 20 amino acids.

And, by the way, one of the amino acids, glycine, over here, you see it right here, violates this rule of chirality.

And, you will recall before I said that because there are four distinct amino acids, four distinct side chains around a central carbon sometimes called the alpha carbon, you always have a handedness of amino acids.

But this notion cannot be respected in the case of glycine seen up here simply because we don't have four distinct, here's the central carbon where I'm pointing with the red, and here these two hydrogens are equivalent to one another.

They are not four distinct chains.

There's only three distinct chains here.

So glycine violates this rule of chirality, of left- and right-handedness. And here, by the way, the side chain, which in all of these cases is depicted as extending off to the right of each amino acid, the side chain is simply an H, simply a proton, a hydrogen atom.

In fact, what we see about these amino acids is that the side chains have quite distinct biochemical properties.

And that begins to impress us with the notion that proteins and their biochemical attributes can be dictated by the identities of the amino acids that are used to construct them.

We can talk about the notion of nonpolar versus polar amino acids, i.e., amino acids which have poor affinity for water.

They don't have a separation of plus and minus charges.

And as a consequence, they are a little bit or quite a bit hydrophobic.

Now, you will say, well, how can they be hydrophobic, because here this oxygen is charged, and here this amine group is charged? That would make it highly hydrophilic.

But keep in mind, when I'm talking about these amino acids, I'm not talking about them when they are in a single amino acid form.

I'm talking about their properties once they have been polymerized into state like this.

And, once they are polymerized into state like this, the NH2 and CO charging, that is, the charge here and the charge here become irrelevant because this oxygen and this amine group are both tied up in covalent bonds.

And, this acquisition of a proton and this shedding of a proton over here cannot occur, because both of these atoms, O and N, are involved in covalent bonds.

So therefore, when we talk about nonpolar and polar amino acids, keep in mind we are focusing on the biochemical properties of the side chain because the central backbone of the polypeptide and the central backbone is defined quite clearly here.

Here's the central backbone, and you see it has a quite repeating structure, N, C, C, N, C, C, N, C, C, this is invariant.

What changes, and what defines the biochemical attributes of this oligopeptide, or a polypeptide, are the identities of these side chains, which again are plotted on this particular graph.

You have a different version in your book off to the right.

Here, you see, we have a proton, a methyl group, a valine, a lucine, an isolucine, and the differences between this suggests these are all quite aliphatic, quite similar to the propane that we talked about last time, or the hexane.

That is to say, these are quite hydrophobic side groups.

And, as such, if there were a polypeptide, we can imagine, and you put the polypeptide in water, you can imagine that these amino acids would not like to be directly confronting the water because of the fact that they are hydrophobic.

Methionine is also a bit hydrophobic.

I'm equivocating there because the S has a slight degree of hydrophilicity.

It has a slight degree of polarity, but not really that much.

And, these aromatic side chains here, because they have these benzene rings, consequently are called aromatic.

These are quite strongly hydrophobic.

So, they really hate to be in the intimate contact with water.

Here, on the other hand, let's look at these side chains because here we have strongly polar molecules, side chains again.

Keep in mind we are focusing on the side chains.

Here we see serine with the hydroxyl group that can form hydrogen bonds with the water, threonine, which has its own hydroxyl group, asparagine, which has two atoms here, this carbonyl and the NH2, both of which can form hydrogen bonds with the water, as can glutamine.

So, these are quite hydrophilic.

They are not as fanatically hydrophilic as these charge molecules where the side chains are not just capable of forming hydrogen bonds.

In this lower group here, the side chains are capable of undergoing ionization.

So they're actually strongly charged.

And here, we see here the carboxyl group, and our aspartic acid and glutamic acid has actually discharged its proton, becoming negatively charged.

These are acidic amino acids, by virtue of the carboxyl group they have, basic amino acids here: arginine, lysine, and histidine, all acquire a positively charged side chain by virtue of these nitrogen here which have a strong affinity for pulling away protons or abstracting protons from the aqueous solvent.

And so, we have a whole gradient of hydrophilicity down to hydrophobicity.

And here, we have intermediate structures.

We also have some very special idiosyncratic kinds of amino acids.

Here is tyrosine, and tyrosine is little bit schizophrenic again.

It has this highly hydrophobic aromatic group here, the benzene ring, which hates to be in water, and the hydroxyl group which actually is a friend of water.

So, here, we have something where its role is quite equivocal.

Here, we have cystine, as indicated here, and what's interesting about the cystine group in this case is the SH group, the side chain, the SH group, because this SH group is able to form bonds with yet other SH groups from other cystines.

So, let's just look at the cystine here for a moment.

You see there's a CH2, and then there's an SH.

So, let's imagine, I'm not going to draw all the atoms here, but let's imagine here we have the CH2 group.

I'm not drawing the backbone, SH, over here.

And, we can imagine another protein chain, another polypeptide chain down here.

Again, I'm not drawing the backbone, but I'm drawing another SH like this.

And, the fact is, under the conditions of oxidation and reduction that operate at least in the extracellular space, one can oxidize this, these two, resulting in the formation of what is known as a disulfide bond.

So, here, we have now for the first notion the idea that the polypeptide chains can be covalently linked to one another through these cross-links, as indicated here.

Conversely, if you add a reducing agent that will add protons back to this, and reduce the oxidation state of the sulfurs, once again causing the disulfide bond to fall apart.

Now, in principle, these disulfide bonds could be used to link two proteins together.

But, more often than not, if you look at the structure of a single protein, here's the structure of a single protein.

And often, there are intramolecular bonds, disulfide bonds, i.e., bonds from one domain of the protein to another, from one part of the protein to the other.

I'll draw them in right here.

Here might be a disulfide bond.

Here might be a disulfide bond, and I could go on and on.

There might be another one over here.

Why do we have these disulfide bonds? Because as we will indicate very shortly, the three-dimensional structure of a protein is very specifically determined.

A protein can only function when it assumes a certain three-dimensional configuration, when it assumes a certain three-dimensional, stereochemical configuration.

When we talk about stereochemistry, we are talking about the three-dimensional structures of molecules, small and large.

And, here, we begin to touch on a theme of how these complex polypeptide chains are able to create proteins that have very specific, often very rigid, structures in three-dimensional space.

Part of this structural rigidity is maintained by these covalent disulfide bonds, which tightly link neighboring regions, or even not so neighboring regions, of a single polypeptide chain, these intramolecular links.

This doesn't preclude there being intermolecular links between two polypeptide chains that are mediated as well by the disulfide bonds.

Here's another very peculiar amino acid because what you see here is at the side chain, which is CH2, CH2, CH2, CH2 is hydrogen bonded here to the amine group.

It's not swinging out in free space.

What we see here is CH2, CH2 is covalent bonded to the amine group.

You pick that up, right? I was just testing you.

OK, so here we see a five-membered ring that's created.

So here, this thing is not swinging out in free space.

It creates a five-membered ring where the end of the side chain is actually covalently linked to the amino group.

And, that also has implications for the structure of proteins because this particular amino acid, whenever it occurs within a polypeptide chain, doesn't have the flexibility of assuming certain configurations that the other ones have whose four side chains are not so encumbered.

None of them has total flexibility, but this one is far more encumbered in the kinds of three-dimensional structures that it can assume.

And, with that in mind, we begin to ask questions about how polypeptide chains assume three-dimensional structure.

If we talk about a polypeptide chain, in our minds, hopefully, there's only 28 combinations.

Oh, am I good or what? Anyhow, all right, so, look here.

And here, you see, this is a typical polypeptide chain.

Here, we have a three letter code.

In truth, there is a single letter code which was introduced around 1965. So, each of the 20 amino acids has its own single letter code.

And, to make a frank and depressing admission, 35 years, 40 years after the single amino acid letter code was instituted, I still haven't learned it.

But, we could learn these three letter codes, which fortunately are present here.

In the single letter code L is lucine, and A is alanine, see, they know it.

This is another example of not being able to teach old dogs new tricks.

Anyhow, so here we see the way, one way by which one might depict an amino acid chain, a polypeptide chain.

And keep in mind, this can go on indefinitely.

As we begin to wrestle with the three-dimensional structure of the chain, we begin to realize the following, and that is that after the chain is initially synthesized, it's initially chaotic.

And, as it extends, it increasingly begins to assume a very specific three-dimensional molecular configuration which is indicated down here.

So, the chaos that operates initially will eventually result in a native configuration over here, which in many respects often represents the lowest free energy state.

Since for the last 40 years, people have been trying to figure out, if you knew the amino acid sequence of this primary polypeptide here, if you knew its primary structure, and when I say, ?primary structure,? what I mean is the sequence of the amino acids.

So, if you knew the primary structure of the amino acids, you should, in principle, be able to develop a computer algorithm that would predict the three-dimensional configuration, which is shown here in a very schematic way, and which we will discuss in much greater detail shortly.

And, the fact is, after 40 years of trying, one still is unable to do that, i.e., if I were to give the primary amino acid sequence of the polypeptide to the smartest biochemists in the world, and there are some very smart ones, he or she could still not tell me what the three-dimensional structure of this protein with total certainty would be.

Why? Because there's an almost infinite number of intramolecular interactions that greatly complicate how the protein assumes the structure.

Moreover, if we talk about this as the native state of the protein, we can imagine that there?s ways of disrupting that because much of this native state is created by intramolecular hydrogen bonds.

Remember, the hydrogen bonds are relatively weak, and if we heat up the temperature, then we can break hydrogen bonds.

And therefore, every time we fry an egg, for example, if we want to get down to Earth, we denature. We break up the native three-dimensional structure of the albumin molecules that constitute the egg white.

And so, when everything turns white, what we've done is to take a native molecule like this, heated it up to temperatures where the intramolecular bonds no longer stabilize.

Notably, hydrogen bonds no longer stabilize this three-dimensional configuration, and we put it into a denatured state, which might be all the way up here.

And, therefore, this acquisition of a native configuration, or a native state, native representing the natural state, is also reversible in many molecules simply by heating them up.

There are to be sure yet other molecules which are different from the egg white from the albumin in egg white where if you cool them back down, they will spontaneously reassume their native structure.

Many proteins, most, will not do so.

Well, again, let's go back to this issue of the acquisition of complex, three-dimensional structure.

And here, we begin to see how some of this structure is acquired and stabilized through these intramolecular hydrogen bonds. And there are many opportunities for these intramolecular hydrogen bonds because here we see one polypeptide chain here, here we see another.

And, we see that the NH2 group right here, I'm sorry, the nitrogen group here with the proton side chain, and the carbonyl group here with the oxygen are not encumbered.

They are, in principle, available to form hydrogen bonds with a polypeptide chain somewhere else.

Now, this other polypeptide chain could once again be from another protein, from another polypeptide.

But more often than not, we are once again dealing with intramolecular cross-links. But in this case, the intramolecular cross-links are not disulfide bonds which are covalent, and hard and stable as a rock in the absence of reducing agents.

Here, we're talking about much weaker bonds, hydrogen bonds which also act between different loops of the protein and serve, once again, to stabilize the three-dimensional structure, the native state of the protein.

And, you can see how these opportunities for forming multiple hydrogen bonds can create an enormous degree of stability.

And, here are some examples of what we now call the secondary structure of the protein.

Just a second ago, or several minutes ago to be honest, and I'm always honest with you, class, the primary structure is the amino acid sequence.

The secondary structure represents configurations like this.

Here is a beta pleated sheet.

And, what we see here in this alpha helix is we have a helical structure where the amine group down here, the NH group, hydrogen bonds with a residue that is, I think, three and a half residues upstream, one, two, there's an amine down there, so, with the carbonyl group that's three and a half residues upstream of it.

This one, once again, reaches three and a half residues upstream.

Not all the hydrogen bonds are shown in the background.

Only the ones on our side of the helix are shown, on the front side of the helix.

But, you can imagine that this can perpetuate itself.

And, each of these carbonyl's may associate with a proton, an NH group that's either above or below that particular residue.

And this, in turn, can create a helical structure.

By the way, proline doesn't fit well.

If you add a proline in here, proline is known in the trade as a helix breaker.

Why? Because it cannot twist itself around to form an alpha helix.

And so, if the primary amino acid were to dictate that a proline would be inserted right here, for example, then this helix might exist down below and above, but it would not be continuous because the presence of a proline is highly disruptive of the formation of an alpha helix.

This means that, in principle, you can make some predictions about the localized structure of a polypeptide by knowing whether or not proline is present, for example.

But that still doesn't give you the power to predict the entire three-dimensional structure of the finished protein itself.

Now, let's agree that this is the secondary structure of the protein, i.e., the various domains which often form alpha helices within a certain segment of the protein or a certain segment of the protein will form beta pleated sheets.

And there are several other less common kinds of secondary structure.

And here, we deal with tertiary structure.

Now we are getting really interesting.

Or, maybe you don't like it.

But some people say it's really interesting because here are the tertiary structures of some arbitrarily chosen proteins.

Here, the tertiary structure of this particular protein, and the identities of these are not given in our textbook.

And, I'm sure if we spent two or three weeks, we could find out what they were.

But anyhow, here is a protein, a three-dimensional structure of a protein which is composed of four alpha helices which go up.

Another alpha helix, alpha helix, alpha helix, alpha helix, they are depicted here, fortunately, in four different colors.

And so, we see that what we talk about tertiary structure, we're talking about how the alpha helices are disposed with respect to one another.

The primary structure of the amino acid sequence is not shown here.

The secondary structure represents these individual alpha helices, and the tertiary structure represents how these alpha helices are arranged vis-?-vis one another.

Here is a protein which is structured much differently.

It's formed of many beta pleated sheets.

We saw that in the last figure, in the last overhead.

You see it as a quite different overall three-dimensional structure.

This could be the beginning of an alpha helix down here, although that's quite equivocal.

And here, we see yet another point.

And that is, as we said before, the tertiary structure independent of these alpha helices and beta pleated sheets may be stabilized by these covalent inter-strand cross-links formed by the cystines.

And in the end, if we put all that together, then we come to the realization that the three-dimensional structure of a protein as determined by the art of x-ray -- There we go.

I actually have a cousin who I won't mention whose son was so dyslexic that when he came to stairways he didn't know whether to put his foot up or down.

OK, anyhow, because I solved it within less than two minutes time, all right, so here we see this is what the three-dimensional structure of a protein looks like.

This is called a space-filling model because here, one draws in, as determined by x-ray crystallography what the, if we could see what a protein looks like, what it actually must look like, where each of the atoms including these side chains is actually depicted.

Before, when we used these far more schematic descriptions like here, we were just talking about the overall structure of the backbone.

We weren't really indicating where the side chains were, and what space they would fill up.

And, if we give them the chance, if we put in all of the other atoms, the side chains, and we create a space-filling model where the actual atoms are shown, this is what the protein would look like.

And the fact of the matter is that all virtually proteins have very specific structures.

It's not as if they can shift from one structure to another.

Once they leave their normal native structure they will lose their ability to do what their normal jobs are.

And, this particular overhead happens to bring in yet another theme that we're going to focus on increasingly, which is, what do proteins do in cells? I'm glad I asked that question.

One of the things they do is they act as catalysts, i.e. , as enzymes.

The fact is, as we will discuss later, virtually all biochemical reactions require an enzyme catalyst in order to propel them forward.

That is to say, if there's a biochemical reaction to occur, almost always it will not occur spontaneously the same way that a hydroxyl ion and a hydrogen will join together spontaneously in water.

Almost all biochemical reactions require the mediation of an enzyme which is a biological catalyst in order to encourage this to happen.

And, almost all catalysts in our cells are proteins.

So, if you have 4,326 distinct biochemical reactions occurring in the cell, that means that there's probably almost as many distinct enzymes, each one of which is assigned to mediate one or another of those distinct biochemical reactions.

And here, we see the fact that this is an enzyme which happens to be called hexokinase.

Recall that the -ase suffix at the end dictates that this is already an enzyme rather than a carbohydrate.

And, this attaches, in fact, a phosphate group onto glucose.

And, what happens is that the glucose, which is the substrate, which is acted upon by the catalyst, is pulled into this site in the protein which is highly specialized to mediate the enzymatic reaction.

Almost all the business of this complex enzyme is carried out right here.

And somehow, a lot of the other amino acids that are located at a distance are doing other things like regulating the activity of the enzyme.

But the actual business end of the enzyme is present in what is called a catalytic cleft, an active site of this enzyme in which the substrates are pulled in and are manipulated and changed chemically by the actions of this particular enzyme.

Now, in saying that virtually all catalysts, but not all, are proteins, I also mean to say that proteins have a second major function in the body.

The first major function is to act as enzymes in catalysts.

The second major function is to create biochemical structures, i.e., structures of different cytoskeleton proteins such as I showed you two lectures ago.

And so, we are going to come repeatedly to the situations where complex structural entities in the cell are composed of different structural proteins.

Again, this is just a prelude to talking about these in greater details, these two major functions of enzymatic catalysis on the one hand, and creating structure on the other hand. And so now, we get to really four hierarchical levels of protein structure.

The primary structure is the amino acid sequence.

And, if we dwell for second on this amino acid sequence, let's realize that any single amino acid can follow any other amino acid.

So, what that means is that if glycine is the first amino acid, as it happens to be here, serine is only one of 20 different possible second amino acids.

Aspartic acid is only one of 20 different third amino acids as the third residue.

We often call these different residues: the first residue, second residue, third residue, fourth residue, and fourth, and so forth.

And, keep in mind, if we think about the combinatorial implications of that, the first amino acid residue can have 20 different ones.

The second can have 20 different identities.

The third can have 20 different identities.

That means if we make a tripeptide - a tripeptide has three amino acids in it.

That means we can make 400 dipeptides, 400 distinct dipeptides, and we can make 8,000 distinct tripeptides.

Now, if you imagine that the average amino acid, the average protein in the cell is, let's say, 150 amino acid residues long, that means that in principle, one could make 20 to the 150th power distinct amino acid sequences because of these absence of any constraints of which amino acid will follow which other amino acids. In other words, if the average polypeptide has this many residues, this is the number of distinct 150 amino acid residue long proteins that one could, in principle, synthesize.

I'm not saying all of them have ever been synthesized since the formation of life on this planet.

Indeed, since some amino acid chains are 4, 5, 600, even 2,000 amino acid residues long, I think the one that is affecting muscular dystrophy is more than 2,000 amino acids.

Dystrophin. Does anybody know here? It's big.

Anyhow, imagine the number of possibilities.

So, combinatorially, life can make almost whatever types of amino acids it would like by dictating the sequence of amino acids.

Now, let's just go and look here again.

There is a secondary structure.

The tertiary structure is the way in which the different alpha helices here or beta pleated sheets are disposed three-dimensionally with respect to one another.

And, the quaternary structure represents how different polypeptides are associated one with the other.

So, for example, hemoglobin is a tetramer.

Hemoglobin doesn't exist as a monomeric protein.

Its solution exists as a tetramer.

And there's two kinds of globin chains.

There is an alpha kind and a beta kind.

And, if we look in a very rough and schematic way at the way that a hemoglobin tetramer is arranged, there are two alpha polypeptide chains and two beta polypeptide chains.

They are not covalently attached to one another.

They are associated with one another via hydrogen bonds and hydrophobic interactions.

And, this is the actual native configuration of globin to alpha and to beta chains.

It doesn't exist as a single amino acid in solution.

And, indeed, most, or I shouldn't say most, but very many proteins exist in these configurations where the tertiary structure represents four different amino acid chains.

And each of these has an N and C terminal.

Each of these is chemically distinct.

These four could probably be taken apart from one another simply by raising the temperature.

And, they associate like this.

And, in the absence of this association, if you just had one of these alphas, or one of these betas, it wouldn't function well at all.

In fact, it might be totally dysfunctional.

One other thing that may be implicit to you, but I haven't said, but that is very important to realize is the following: Let's imagine that this is the three-dimensional structure of the protein, as it may well be.

Let's now think about hydrophobic and hydrophilic amino acids.

The hydrophobic amino acids hate to be present water.

And therefore, they are, we can imagine this case correctly, tucked away inside the interstices of the protein far way from the surface.

They don't have any contact with water.

Conversely, the highly charged hydrophilic amino acids are actually sticking out at the surface.

And this begins to yield yet another insight into how the three-dimensional stereochemistry of proteins is maintained and dictated because the hydrophobic amino acids, through hydrophobic interactions, stabilize the inner core of the protein that is well shielded from the aqueous solvent.

The hydrophilic amino acids are on the outside.

They like to be in intimate contact with the water.

So, we already now have talked about a number of distinct different interactions that are responsible for creating the three-dimensional stereochemistry of the protein.

First of all, there are the disulfide bonds, which create chain-to-chain covalent interactions.

They are the hydrogen bonds in which different chains can interact one another.

And there are these hydrophobic and hydrophilic interactions.

And, there are some relatively inconsequential van der Waals interactions, which are really not worth discussing although some people get really excited about them.

So, here we now begin to see that we have really interesting polypeptides unlike the boring polypeptides that are ultimately the way one must judge carbohydrates.

Some people think carbohydrate chemistry is really interesting.

But it really isn't that interesting because you just have the same monomer in a hundred, or 500 stretches.

Here, a protein is much more interesting because of this enormous variability in amino acid sequence, and the consequent ability to create all kinds of chemical reactivities and structures because of these 20 different amino acids.

If we were to imagine life on another planet, and we imagine that there were, let's say, amino acid-like molecules that were part of life, maybe that other life wouldn't have exactly the same 20 amino acids as we do.

It almost certainly would be a water base the way we are.

But, it would also rely on hydrogen bonds and hydrophilicity, and hydrophobicity interactions in order to dictate the three-dimensional structure.

In the absence of this very specific three-dimensional structure I will tell you that this enzyme could not function.

And, if you were to take this enzyme, if it were typical enzyme and you were to heat it up briefly, even often slightly above normal body temperature, it might denature, i.e., it might lose its three-dimensional structure irreversibly.

And, once it was denatured, this process of denaturation, it might not be able to spontaneously reassume that pre-existing three-dimensional configuration and therefore would forever be inactive.

That means to say very explicitly that even though the amino acids that are creating that active catalytic site remain there.

Their highly specific three-dimensional disposition is critical for the continued actions of this enzyme.

And, once their three-dimensional dispositions are shifted around through the process of interactions, then, we have trouble because the enzyme can no longer do its assigned task.

We are going to go now to an even higher order of complexity in one sense.

We are going to go to the royalty of the macromolecules, which are the nucleic acids.

Of course, protein chemists would take great umbrage at the very notion that there are things better than proteins.

But, the fact of the matter is, I can't show you that overhead because it's from the other textbook which is copyright, and we are being filmed.

How many people have had the backs of their heads immortalized on these videos? Did you call home and ask anybody to identify you? I don't know, but soon each of us has the limelight for 15 minutes a lifetime, right? So, you'll have your 15 minutes.

Here are some nucleic acids.

And let's look at these nucleic acids and the way they are put together.

Keep in mind to anticipate what we are going to say next time, once again, we want to make end-to-end aggregates.

We want to polymerize molecules.

And in this case, we want to do so once again through a dehydration reaction.

And, moreover, just to look at the building blocks of nucleic acids, we start again in this case with two pentoses.

Recall that they have fuor carbons: one, two, three, four, did I say four? You know I meant five.

So, whenever I say four from now on, I mean, or, whenever I say four I may also mean four.

OK, one, two, three, four five.

And let's look at the two basic kinds of pentose molecules that are present in nucleic acid because they define the essential difference between DNA and RNA.

Here's a regular old rather familiar kind of pentose with five carbons.

And here's an unfamiliar kind of pentose which we call deoxyribose. Why? Because if you look really carefully, you'll see that the hydroxyl group here, which should be present in any self-respecting pentose is missing, and is replaced simply by a hydrogen group, i.e., it's lost its oxygen, whence cometh the word, ?deoxyribose,? and ultimately clearly the word, ?deoxyribose nucleic acid.?

And one of the attributes, one of the virtues of carbohydrates, as we discussed last time, were these numerous hydroxyl groups, which represent opportunities for all kinds of dehydration reactions which can enable one to build much more complex molecules.

And here, we see the structure of, for example, a deoxyribonucleotide whose detailed structure we'll get into next time.

But just, let's look at how these hydroxyl groups have been used.

The hydroxyl group, in this case in DNA, and by the way notice that the structure I've shown here, there's a side chain attached here, and a side chain attached here.

And neither of those depends on whether or not there is a hydrogen or a hydroxyl right here.

And look at what's happened here.

Here, we have this hydroxyl over here to which a base has been attached covalently, once again, by a dehydration reaction.

And here, we have a situation where actually three phosphate groups have been attached to the hydroxyl group in this direction.

And, this represents the basic building blocks of nucleic acids.

Now, one of the things that's going to be really important and that you're going to have to memorize, I told you, you weren't going to have to memorize anything.

But you didn't believe me, did you? Good.

OK, one of the things you're going to have to memorize is the numbering system here.

This is number one, two, three, four, five, or to be totally frank, and you know I'm always that, one prime, two prime, three prime, four prime, five prime.

And that numbering system, it turns out, is going to be very important for our subsequent discussions.

Notice here that, for example, it's here at the two prime position that this deoxyribose is lacking the oxygen that is present normally in RNA.

And, with all this in mind, we will wait in great suspense until Wednesday when we actually talk about how this is exploited to make highly complex polymers.


David A. Drummond, PhD

Dr. Drummond is an Associate Professor of Biochemistry & Molecular Biology and Human Genetics. His group studies how cells respond to stress at the molecular level, focusing on formation and dissolution of large assemblies of proteins and RNA during and after stresses such as heat shock. Drummond's lab uses a wide range of techniques, including in vivo imaging, in vitro reconstitution and mechanistic biochemistry, quantitative proteomics, and molecular evolutionary analyses. Because many features of stress-triggered assembly processes are shared across eukaryotes, including humans, the group employs budding yeast, Saccharomyces cerevisiae, as a model organism.

Harvard University
Cambridge, MA
- Systems biology
2011

California Institute of Technology
Pasadena, CA
Ph.D. - Computation and neural systems
2006

Princeton University
Princeton, NJ
B.S.E. - Mechanical and aerospace engineering
1995

Daily Cycles of Reversible Protein Condensation in Cyanobacteria.
Pattanayak GK, Liao Y, Wallace EWJ, Budnik B, Drummond DA, Rust MJ. Daily Cycles of Reversible Protein Condensation in Cyanobacteria. Cell Rep. 2020 Aug 18 32(7):108032.
PMID: 32814039

Transient intracellular acidification regulates the core transcriptional heat shock response.
Triandafillou CG, Katanski CD, Dinner AR, Drummond DA. Transient intracellular acidification regulates the core transcriptional heat shock response. Elife. 2020 08 07 9.
PMID: 32762843

Cellular sensing by phase separation: Using the process, not just the products.
Yoo H, Triandafillou C, Drummond DA. Cellular sensing by phase separation: Using the process, not just the products. J Biol Chem. 2019 05 03 294(18):7151-7159.
PMID: 30877200

An Escherichia coli Nitrogen Starvation Response Is Important for Mutualistic Coexistence with Rhodopseudomonas palustris.
McCully AL, Behringer MG, Gliessman JR, Pilipenko EV, Mazny JL, Lynch M, Drummond DA, McKinlay JB. An Escherichia coli Nitrogen Starvation Response Is Important for Mutualistic Coexistence with Rhodopseudomonas palustris. Appl Environ Microbiol. 2018 07 15 84(14).
PMID: 29728387

Stress-Triggered Phase Separation Is an Adaptive, Evolutionarily Tuned Response.
Riback JA, Katanski CD, Kear-Scott JL, Pilipenko EV, Rojek AE, Sosnick TR, Drummond DA. Stress-Triggered Phase Separation Is an Adaptive, Evolutionarily Tuned Response. Cell. 2017 03 09 168(6):1028-1040.e19.
PMID: 28283059

Heat Shock Factor 1: From Fire Chief to Crowd-Control Specialist.
Triandafillou CG, Drummond DA. Heat Shock Factor 1: From Fire Chief to Crowd-Control Specialist. Mol Cell. 2016 07 07 63(1):1-2.
PMID: 27392142

Reversible, Specific, Active Aggregates of Endogenous Proteins Assemble upon Heat Stress.
Wallace EW, Kear-Scott JL, Pilipenko EV, Schwartz MH, Laskowski PR, Rojek AE, Katanski CD, Riback JA, Dion MF, Franks AM, Airoldi EM, Pan T, Budnik BA, Drummond DA. Reversible, Specific, Active Aggregates of Endogenous Proteins Assemble upon Heat Stress. Cell. 2015 Sep 10 162(6):1286-98.
PMID: 26359986

Dying mRNA Tells a Story of Its Life.
Wallace EW, Drummond DA. Dying mRNA Tells a Story of Its Life. Cell. 2015 Jun 04 161(6):1246-8.
PMID: 26046434

Nephrocalcinosis in Calcium Stone Formers Who Do Not have Systemic Disease.
Bhojani N, Paonessa JE, Hameed TA, Worcester EM, Evan AP, Coe FL, Borofsky MS, Lingeman JE. Nephrocalcinosis in Calcium Stone Formers Who Do Not have Systemic Disease. J Urol. 2015 Nov 194(5):1308-12.
PMID: 25988516

Accounting for experimental noise reveals that mRNA levels, amplified by post-transcriptional processes, largely determine steady-state protein levels in yeast.
Csárdi G, Franks A, Choi DS, Airoldi EM, Drummond DA. Accounting for experimental noise reveals that mRNA levels, amplified by post-transcriptional processes, largely determine steady-state protein levels in yeast. PLoS Genet. 2015 May 11(5):e1005206.
PMID: 25950722

Pew Scholar in the Biomedical Sciences
Pew Charitable Trusts
2012 - 2016

Sloan Research Fellow
Alfred P. Sloan Foundation
2012 - 2014


Research Assistant – Protein Biochemistry and Cell Biology

Transition Bio is an innovative, early-stage biotechnology company with the vision of being the world leader in the discovery, analysis, and modulation of biological condensates. The company is driven by hypothesis-free drug discovery and diagnostics, and develops first-in-class technology platforms for condensate analysis and drug screening.

Transition Bio is looking for a talented and highly motivated Research Assistant in Protein Biochemistry and Cell Biology to join our team in Cambridge, UK. The successful candidate will have a BSc/MSc/Ph.D. degree and at least two years of hands-on lab experience. They will possess a thorough knowledge in protein production technology for all three commonly used protein expression systems (bacteria, insect, and mammalian). The applicant must be well versed in basic molecular biology and cell biology techniques, and must have experience in working with chromatography platforms (e.g., AKTA purification system) including the use of affinity, ion-exchange, immunoaffinity, size-exclusion chromatography. Knowledge of working with phase separating proteins is an asset. The candidate must have the ability to work effectively as part of a team and have the potential to be able to work independently upon training.

Key Responsibilities:

  • Produce proteins from heterologous expression systems including insect (baculovirus), mammalian, yeast, and bacterial cells
  • Purify proteins using state-of-the-art chromatography platforms and other analytical methods to ensure production of the highest quality candidate proteins
  • Perform and develop cell biology protocols for purification and isolation of membraneless organelles
  • Execute cloning strategies for construct generation and conduct assays for molecular, biophysical, and structural characterization of proteins
  • Analyse results, troubleshoot technical difficulties, and implement solutions present results at meetings
  • Conduct research projects in a team setting, progressing the production of condensate forming proteins and the development of cell biology protocols
  • Maintain and implement good laboratory practices, including accurate laboratory notebook systems, and follow laboratory safety guidelines and practices
  • Work effectively with a cross-functional team to contribute to the vision, strategy, and tactics of the organization

Basic Qualifications:

  • BSc/MA/Ph.D. in Biochemistry/Protein Science/Cell Biology (or a similar field) and preferably industry experience in protein biochemistry, molecular biology, cell biology or related disciplines
  • Firm knowledge on recombinant protein expression and purification strategies using insect (baculovirus), mammalian, yeast, and bacterial expression systems
  • Practical experience in protein purification (e.g., affinity, ion, and size exclusion chromatography) using both state-of-the-art FPLC / HPLC instruments as well as batch purification approaches
  • Experience in standard molecular biology and cell biology techniques including cell culture, DNA purification, PCR and primer design, cloning techniques, plasmid isolation, and DNA sequencing
  • Experience in standard protein characterization techniques including gel electrophoresis, UV/ VIS and other protein analytical techniques
  • Ability to organise, analyse, and deliver information in a concise, accurate, and professional manner strong written and oral communication skills excellent data management skills
  • A high degree of integrity and team orientation a can-do motivating attitude
  • Ability and desire to work in a fast-paced, research-driven, and entrepreneurial environment

Preferred Qualifications:

  • Experience in the design, expression, and purification of phase separating protein systems
  • 2+ years of industry or post-doctoral experience in protein biochemistry, molecular biology, or related disciplines
  • Prior experience in therapeutic protein discovery, biochemistry and cell biology research


Watch the video: Biochemistry part 1. شرح Biology Barrons (February 2023).